FDA approves Cyberonics' new VNS generator
This article was originally published in Clinica
The US FDA has approved AspireHC, a generator for vagus nerve stimulation (VNS) therapy developed by Cyberonics, via a premarket approval (PMA) supplement. The firm's VNS device is approved to treat drug-resistant epilepsy and depression by using electrodes to stimulate the vagus nerve in the neck. The fifth-generation AspireHC generator is implanted in the chest and sends impulses via leads to these electrodes. The device's main advantage over previous-generation products is a longer battery life, which could range from three to 11 years depending on how aggressively the patient is managed, Cyberonics told Clinica. "Aspire will probably be ideal for patients who need aggressive treatment," a spokesperson said.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.